<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02470585</url>
  </required_header>
  <id_info>
    <org_study_id>M13-694</org_study_id>
    <secondary_id>2014-005070-11</secondary_id>
    <nct_id>NCT02470585</nct_id>
  </id_info>
  <brief_title>Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</brief_title>
  <acronym>VELIA</acronym>
  <official_title>A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gynecologic Oncology Group;Australia New Zealand Gynaecological Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study was to evaluate whether progression-free survival (PFS)&#xD;
      was prolonged with the addition of veliparib to standard platinum-based chemotherapy&#xD;
      (carboplatin/paclitaxel [C/P]) and continued as maintenance therapy compared with&#xD;
      chemotherapy alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants were randomized in a 1:1:1 ratio to one of three arms. Randomization in the&#xD;
      entire population was stratified according to the timing of surgery and residual disease&#xD;
      status (any residual disease after primary surgery vs. no residual disease after primary&#xD;
      surgery vs. interval surgery) and the paclitaxel schedule (weekly vs. every 3 -weeks), stage&#xD;
      of disease (III vs. IV), geographic region (Japan vs. North America and rest of world [ROW]),&#xD;
      and germline breast cancer susceptibility gene (BRCA) mutation status (positive versus&#xD;
      negative or Unknown).&#xD;
&#xD;
      Cytoreductive surgery could be performed before randomization and the initiation of study&#xD;
      treatment (primary) or after 3 cycles of study treatment (interval). The weekly or&#xD;
      every-3-week paclitaxel schedule and the choice of primary or interval cytoreductive surgery&#xD;
      were determined at the discretion of the investigator.&#xD;
&#xD;
      The primary objective was evaluated in the BRCA-deficient cohort, participants with&#xD;
      homologous recombination deficiency (HRD), and the intention-to-treat (ITT) population. These&#xD;
      populations were sequentially inclusive, with the HRD population including the BRCA-deficient&#xD;
      population, and the ITT population including the HRD and BRCA-deficient populations. The&#xD;
      BRCA-deficient population was defined as participants with either a germline (gBRCA) and/or&#xD;
      tissue-based (tBRCA) deleterious or suspected deleterious mutation in BRCA1 or BRCA2&#xD;
      confirmed by centralized testing. The HRD population was defined as participants with HRD&#xD;
      tumors based on HRD score or presence of a deleterious or suspected deleterious mutation in&#xD;
      BRCA1 or BRCA2 as determined by centralized testing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 29, 2015</start_date>
  <completion_date type="Anticipated">December 8, 2026</completion_date>
  <primary_completion_date type="Actual">May 3, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) in the BRCA-deficient Population</measure>
    <time_frame>From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.</time_frame>
    <description>PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death if disease progression was not reached. If the participant did not have an event of disease progression or death prior to the analysis cut-off date, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method. The analysis of PFS occurred when the protocol-specified number of PFS events was reached.&#xD;
Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) in the Homologous Recombination Deficiency Cohort</measure>
    <time_frame>From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.</time_frame>
    <description>PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death if disease progression was not reached. If the participant did not have an event of disease progression or death, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method. The primary analysis of PFS occurred when the protocol-specified number of PFS events was reached and was performed in 3 sequentially inclusive populations.&#xD;
Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.&#xD;
.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) in the Intention-to-treat Population</measure>
    <time_frame>From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.</time_frame>
    <description>PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death (all causes of mortality) if disease progression was not reached. If the participant did not have an event of disease progression according to RECIST criteria (as or death, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method.&#xD;
Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.&#xD;
The primary analysis of PFS occurred when the protocol-specified number of PFS events was reached.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Approximately 8 years from randomization.</time_frame>
    <description>OS is defined as the time from the day the participant was randomized to the date of death. All events of death will be included, regardless of whether the event occurs while the participant is still taking study drug, or after discontinuation of study drug. If a participant has not died, then the data will be censored at the date the participant is last known to be alive.&#xD;
The final analysis of OS will occur when the pre-specified number of events has occurred in the ITT and HRD populations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Related Symptom (DRS) Score in the BRCA-mutation Population</measure>
    <time_frame>Baseline and Day 1 of Cycles 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35</time_frame>
    <description>The Disease Related Symptom score is a subset of the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18), which evaluates nine symptoms related to ovarian cancer. The NFOSI-18 DRS score ranges from 0 to 36, with higher scores indicating a lower burden of symptoms and a score of 0 being severely symptomatic. A 3-point difference was defined as clinically meaningful. A positive change from Baseline indicates improvement.&#xD;
Change from Baseline was calculated using a used a mixed-model for repeated measures (MMRM) with treatment, stratification factors of residual disease and stage of disease, time point and treatment-by-time point interaction as fixed effect factors, and Baseline DRS score as a covariate.&#xD;
DRS was not included in the fixed-sequence testing procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Related Symptom (DRS) Score in the HRD Population</measure>
    <time_frame>Baseline and Day 1 of Cycles 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35</time_frame>
    <description>The Disease Related Symptom score is a subset of the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18), which evaluates nine symptoms related to ovarian cancer. The NFOSI-18 DRS score ranges from 0 to 36, with higher scores indicating a lower burden of symptoms and a score of 0 being severely symptomatic. A 3-point difference was defined as clinically meaningful. A positive change from Baseline indicates improvement.&#xD;
Change from Baseline was calculated using a used a mixed-model for repeated measures (MMRM) with treatment, stratification factors of residual disease and stage of disease, time point and treatment-by-time point interaction as fixed effect factors, and Baseline DRS score as a covariate.&#xD;
DRS was not included in the fixed-sequence testing procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Related Symptom (DRS) Score in the ITT Population</measure>
    <time_frame>Baseline and Day 1 of Cycles 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35</time_frame>
    <description>The Disease Related Symptom score is a subset of the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18), which evaluates nine symptoms related to ovarian cancer. The NFOSI-18 DRS score ranges from 0 to 36, with higher scores indicating a lower burden of symptoms and a score of 0 being severely symptomatic. A 3-point difference was defined as clinically meaningful. A positive change from Baseline indicates improvement.&#xD;
Change from Baseline was calculated using a used a mixed-model for repeated measures (MMRM) with treatment, stratification factors of residual disease, stage of disease, choice of paclitaxel dosing regimen and BRCA-deficient status, time point and treatment-by-time point interaction as fixed effect factors, and Baseline DRS score as a covariate.&#xD;
DRS was not included in the fixed-sequence testing procedure.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1140</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Ovarian Neoplasm</condition>
  <arm_group>
    <arm_group_label>Placebo + Carboplatin + Paclitaxel -&gt; Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive placebo to veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by placebo monotherapy continuous dosing for an additional thirty 21-day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Veliparib + Carboplatin + Paclitaxel -&gt; Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 150 mg veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by placebo monotherapy continuous dosing for an additional thirty 21-day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Veliparib + Carboplatin + Paclitaxel -&gt; Veliparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 150 mg veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by 300/400 mg veliparib monotherapy orally twice a day for an additional thirty 21-day cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Veliparib</intervention_name>
    <description>Capsules for oral administration</description>
    <arm_group_label>Veliparib + Carboplatin + Paclitaxel -&gt; Placebo</arm_group_label>
    <arm_group_label>Veliparib + Carboplatin + Paclitaxel -&gt; Veliparib</arm_group_label>
    <other_name>ABT-888</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Administered by intravenous infusion, either 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle (weekly dosing), or 175 mg/m² of BSA on Day 1 of each 21-day cycle (3-week dosing).</description>
    <arm_group_label>Placebo + Carboplatin + Paclitaxel -&gt; Placebo</arm_group_label>
    <arm_group_label>Veliparib + Carboplatin + Paclitaxel -&gt; Placebo</arm_group_label>
    <arm_group_label>Veliparib + Carboplatin + Paclitaxel -&gt; Veliparib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Administered by intravenous infusion at an area under the curve (AUC) of 6 mg/mL/min every 3 weeks.</description>
    <arm_group_label>Placebo + Carboplatin + Paclitaxel -&gt; Placebo</arm_group_label>
    <arm_group_label>Veliparib + Carboplatin + Paclitaxel -&gt; Placebo</arm_group_label>
    <arm_group_label>Veliparib + Carboplatin + Paclitaxel -&gt; Veliparib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo to Veliparib</intervention_name>
    <description>Capsules for oral administration</description>
    <arm_group_label>Placebo + Carboplatin + Paclitaxel -&gt; Placebo</arm_group_label>
    <arm_group_label>Veliparib + Carboplatin + Paclitaxel -&gt; Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologic diagnosis of International Federation of Gynecology and Obstetrics (FIGO)&#xD;
             Stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma,&#xD;
             with the appropriate tissue available for histologic evaluation.&#xD;
&#xD;
          2. High-grade serous adenocarcinoma&#xD;
&#xD;
          3. Willing to undergo testing for gBRCA.&#xD;
&#xD;
          4. Adequate hematologic, renal, and hepatic function.&#xD;
&#xD;
          5. Neuropathy (sensory and motor) less than or equal to Grade 1.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.&#xD;
&#xD;
          7. Participants who undergo primary cytoreductive surgery must be entered between 1 and&#xD;
             12 weeks after surgery. Participants undergoing interval surgery must have a tumor&#xD;
             sample confirming the histological diagnosis prior to enrollment.&#xD;
&#xD;
          8. Participants with measurable disease or non-measurable disease are eligible.&#xD;
             Participants may or may not have cancer-related symptoms.&#xD;
&#xD;
          9. Participant has one of the following available for pharmacodynamic analyses including&#xD;
             somatic BRCA testing: Archived diagnostic formalin-fixed paraffin embedded (FFPE)&#xD;
             tumor tissue; or tumor tissue biopsy collected prior to Cycle 1 Day 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Endometrioid adenocarcinoma, carcinosarcoma, undifferentiated carcinoma, mixed&#xD;
             epithelial adenocarcinoma, adenocarcinoma not otherwise specified, mucinous&#xD;
             adenocarcinoma, clear cell adenocarcinoma, low-grade serous adenocarcinoma, or&#xD;
             malignant Brenner's tumor.&#xD;
&#xD;
          2. Participants with synchronous primary endometrial cancer, or a past history of&#xD;
             endometrial cancer unless all of the following conditions are met: endometrial cancer&#xD;
             stage not greater than IA, no vascular or lymphatic invasion, no poorly differentiated&#xD;
             subtypes including serous, clear cell, or other FIGO grade 3 lesions.&#xD;
&#xD;
          3. Participants with any evidence of other invasive malignancy being present within the&#xD;
             last 3 years (with the exception of non-melanoma skin cancer). Participants are also&#xD;
             excluded if their previous cancer treatment contraindicates this protocol's therapy.&#xD;
&#xD;
          4. Received prior radiotherapy to any portion of the abdominal cavity or pelvis.&#xD;
&#xD;
          5. Received prior chemotherapy for any abdominal or pelvic tumor.&#xD;
&#xD;
          6. Clinically significant uncontrolled condition(s).&#xD;
&#xD;
          7. Known history of allergic reaction to Cremophor-paclitaxel, carboplatin, Azo-Colourant&#xD;
             Tartrazine (also known as FD&amp;C Yellow 5 or E102), Azo-Colourant Orange Yellow-S (also&#xD;
             known as FD&amp;C Yellow 6 or E110) or known contraindications to any study supplied drug.&#xD;
&#xD;
          8. History or evidence upon physical examination of central nervous system (CNS) disease,&#xD;
             including primary brain tumor, any brain metastases, or history of cerebrovascular&#xD;
             accident (CVA, stroke), transient ischemic attack (TIA) within 6 months of Cycle 1 Day&#xD;
             1.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham - Main /ID# 138087</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Valley Gyn-Onc /ID# 139548</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Alabama /ID# 138091</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604-3302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alaska Womens Cancer Care /ID# 138231</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508-4684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC-HOPE /ID# 142002</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711-2701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC-HOPE /ID# 143805</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711-2701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC-HOPE /ID# 143806</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711-2701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC-HOPE /ID# 143808</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711-2701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Cancer Center - North Campus /ID# 138084</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719-1478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Cancer Center - North Campus /ID# 139495</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719-1478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences /ID# 138253</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Muir Medical Center /ID# 139618</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsd /Id# 140323</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Ct /ID# 147526</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente /ID# 141305</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles /ID# 138179</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Care Assoc /ID# 139498</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-4304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ CA, Irvine Med Ctr /ID# 139613</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center - Main /ID# 144439</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Ctr /ID# 138177</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - San Francisco /ID# 142051</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ California, San Francisco /ID# 138178</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-2204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-Santa Clara /ID# 142053</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95051-5173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Med /ID# 139450</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-2200</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palo Alto Medical Foundation /ID# 139452</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94086</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Ctr-Vallejo /ID# 139492</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589-2441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente- Walnut Creek /ID# 142052</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente, Waterpark III Institute for Health Research /ID# 139499</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Colorado Cancer Center /ID# 138016</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Healthcare /ID# 138184</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>6053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University /ID# 138056</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami /ID# 139457</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Cancer Associates /ID# 140321</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Memorial Health Care /ID# 138180</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center /ID# 138061</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Regents University /ID# 138085</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IACT Health /ID# 138058</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904-8946</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Health Univ Med Ctr /ID# 138019</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's/Candler /ID# 138090</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Queens Medical Center /ID# 141709</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center /ID# 140319</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center /ID# 143491</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago /ID# 139612</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1443</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem - Evanston Hospital /ID# 139451</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharma, Hinsdale, IL /ID# 140326</name>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <zip>60521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Lutheran General Hosp /ID# 139489</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ School Medicine /ID# 139610</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent /ID# 139537</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic, PC /ID# 139455</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics /ID# 138082</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Kansas Med Ctr /ID# 140322</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health Lexington /ID# 139542</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Chandler Medical Center /ID# 138060</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute /ID# 139567</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202-3700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MMP Women's Health /ID# 139544</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Baltimore Medical Ctr /ID# 138049</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore /ID# 141306</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weinberg Cancer Inst Franklin /ID# 138235</name>
      <address>
        <city>Rossville</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center /ID# 139456</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center /ID# 139458</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University /ID# 139601</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-2013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System /ID# 139536</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital /ID# 139550</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073-6710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester /ID# 139565</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mmcorc /Id# 139534</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Dominic Hospital /ID# 138241</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ellis Fischel Cancer Center /ID# 139571</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212-1000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University-School of Medicine /ID# 138089</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research For the Ozarks /ID# 139538</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ferrell-Duncan Clinic /ID# 143484</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital /ID# 139600</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Womens Cancer Center of Nevada /ID# 138092</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renown Regional Medical Center /ID# 138237</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center /ID# 139502</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Ctr at Coop /ID# 139616</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack Univ Med Ctr /ID# 143776</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico /ID# 144220</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SW Gynecologic Oncology Assoc /ID# 147097</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Cancer Care Associates /ID# 138234</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center /ID# 139585</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Medical Center /ID# 139533</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center /ID# 138052</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health /ID# 139572</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Med Mt. Sinai /ID# 139617</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center /ID# 138252</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3729</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center /ID# 138017</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065-6007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center /ID# 154464</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065-6007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University - Downtown /ID# 139513</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Womens Cancer Centers /ID# 139614</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ NC Chapel Hill /ID# 138547</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514-4220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium Health Carolinas Medical Center /ID# 139568</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Cancer Center /ID# 139590</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center /ID# 138048</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center /ID# 139588</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati /ID# 139619</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0585</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Hosp Cleveland /ID# 139615</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Hospital /ID# 144403</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Main Campus /ID# 139501</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University - Columbus /ID# 138053</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus NCORP /ID# 139587</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Womens Cancer Center /ID# 138062</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429-1226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillcrest Hospital /ID# 144404</name>
      <address>
        <city>Mayfield Heights</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Oklahoma HSC /ID# 138020</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cancer Specialists /ID# 138059</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute /ID# 140318</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401-6043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente, NW /ID# 138249</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital /ID# 138086</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania /ID# 140079</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-5502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University /ID# 138239</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107-4414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center /ID# 149479</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh MC /ID# 138054</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reading Hospital /ID# 138057</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Infants Hospital /ID# 138083</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina /ID# 138181</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Research/USD /ID# 139624</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104-8805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanoogas Program in Womens /ID# 139545</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Austin Central /ID# 143817</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - South Austin /ID# 143818</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Bedford /ID# 143814</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Medical City Dallas /ID# 143809</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Medical City Dallas /ID# 143812</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Forth Worth /ID# 143811</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104-2150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital - Scurlock Tower /ID# 138232</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital /ID# 138238</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - The Woodlands /ID# 142003</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler /ID# 143810</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah /ID# 138250</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112-5500</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center /ID# 138251</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401-1473</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia /ID# 138088</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carilion Roanoke Memorial Hosp /ID# 139602</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skagit Valley Medical Center /ID# 139586</name>
      <address>
        <city>Mount Vernon</city>
        <state>Washington</state>
        <zip>98273</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Regional Cancer Ctr /ID# 149872</name>
      <address>
        <city>Puyallup</city>
        <state>Washington</state>
        <zip>93872</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multicare Institute for Research and Innovation /ID# 143485</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HSHS St. Vincent Hospital /ID# 139453</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert &amp; the Medical College of Wisconsin /ID# 139449</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3522</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coffs Harbour Health Campus /ID# 145132</name>
      <address>
        <city>Coffs Harbour</city>
        <state>New South Wales</state>
        <zip>2450</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gosford Hospital /ID# 145299</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George Hospital /ID# 145138</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle Private Hospital /ID# 145834</name>
      <address>
        <city>Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Prince of Wales Hospital /ID# 145134</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Cancer Institute /ID# 145681</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle /ID# 145139</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital /ID# 145137</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Medical Day Care Ctr /ID# 145133</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Townsville Hospital /ID# 149163</name>
      <address>
        <city>Douglas</city>
        <state>Queensland</state>
        <zip>4814</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital /ID# 145135</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Centre /ID# 148208</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae Limited /ID# 145682</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital /ID# 150071</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Health /ID# 145297</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabrini Health /ID# 145142</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Womens Hospital /ID# 145136</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital /ID# 145140</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John of God Subiaco Hosp /ID# 147742</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hc Ufmg /Id# 137156</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Lucas da PUCRS /ID# 137157</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cancer de Barretos /ID# 137121</name>
      <address>
        <city>Barretos</city>
        <state>Sao Paulo</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Referencia da Saude da Mulher - Hospital Perola Byington /ID# 137120</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>01317-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA) /ID# 137155</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20231-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vejle Sygehus /ID# 137262</name>
      <address>
        <city>Vejle</city>
        <state>Syddanmark</state>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionshospitalet Herning /ID# 137260</name>
      <address>
        <city>Herning</city>
        <zip>7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus /ID# 137434</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lady Davis Carmel MC /ID# 137537</name>
      <address>
        <city>Haifa</city>
        <zip>3436212</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center /ID# 137435</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center /ID# 139397</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center /ID# 137436</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center /ID# 137536</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital /ID# 148398</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center /ID# 149133</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital /ID# 148697</name>
      <address>
        <city>Kurume-shi</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University Hospital /ID# 147721</name>
      <address>
        <city>Shiwa-gun</city>
        <state>Iwate</state>
        <zip>028-3695</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital /ID# 154169</name>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mie University Hospital /ID# 149169</name>
      <address>
        <city>Tsu-shi</city>
        <state>Mie</state>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital /ID# 149818</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata University Medical &amp; Dental Hospital /ID# 149488</name>
      <address>
        <city>Niigata-shi</city>
        <state>Niigata</state>
        <zip>951-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital /ID# 154947</name>
      <address>
        <city>Osaka-sayama</city>
        <state>Osaka</state>
        <zip>5898511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center /ID# 147723</name>
      <address>
        <city>Sunto-gun</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hosp JFCR /ID# 148436</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital /ID# 148326</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamagata University Hospital /ID# 153646</name>
      <address>
        <city>Yamagata-shi</city>
        <state>Yamagata</state>
        <zip>990-9585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Cancer Center /ID# 148327</name>
      <address>
        <city>Akashi</city>
        <zip>673-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai Rosai Hospital /ID# 149237</name>
      <address>
        <city>Amagasaki</city>
        <zip>660-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jikei Univ. Kashiwa Hosp. /ID# 149238</name>
      <address>
        <city>Kashiwa-shi</city>
        <zip>277-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marianna Univ Hospital /ID# 149327</name>
      <address>
        <city>Kawasaki</city>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Kure Medical Center and Ch /ID# 148569</name>
      <address>
        <city>Kure</city>
        <zip>737-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shikoku Cancer Center /ID# 148382</name>
      <address>
        <city>Matsuyama</city>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute /ID# 150778</name>
      <address>
        <city>Osaka</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido Cancer Center /ID# 148570</name>
      <address>
        <city>Sapporo</city>
        <zip>003-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jikei University Hospital /ID# 148691</name>
      <address>
        <city>Tokyo</city>
        <zip>105-8461</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center /ID# 139404</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggido</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital /ID# 136908</name>
      <address>
        <city>성북구</city>
        <state>Gyeonggido</state>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital /ID# 136835</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center /ID# 136834</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital /ID# 136909</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center /ID# 136836</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital /ID# 145123</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie C. Kliniczne /ID# 138021</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reynals /ID# 137298</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Vall d'Hebron /ID# 137297</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona /ID# 137300</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clin Univ San Carlos /ID# 137402</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Univ 12 de Octubre /ID# 137299</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Univ Madrid Sanchinarro /ID# 137414</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Inst Valenciano Onc /ID# 137403</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich Univ Hosp /ID# 137969</name>
      <address>
        <city>Norwich</city>
        <state>Norfolk</state>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson west of scotland cancer center /ID# 137965</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital /ID# 137967</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Paget University Hosp /ID# 137970</name>
      <address>
        <city>Great Yarmouth</city>
        <zip>NR31 6LA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imanova Limited, Hammersmith Hospital /ID# 137966</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Univ Hosp NHS Trust /ID# 137973</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Denmark</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
  </removed_countries>
  <reference>
    <citation>Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019 Dec 19;381(25):2403-2415. doi: 10.1056/NEJMoa1909707. Epub 2019 Sep 28.</citation>
    <PMID>31562800</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 10, 2015</study_first_submitted>
  <study_first_submitted_qc>June 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2015</study_first_posted>
  <results_first_submitted>August 4, 2020</results_first_submitted>
  <results_first_submitted_qc>August 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2020</results_first_posted>
  <disposition_first_submitted>April 29, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>April 29, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 4, 2020</disposition_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Veliparib</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Overall Survival</keyword>
  <keyword>ABT-888</keyword>
  <keyword>Randomized</keyword>
  <keyword>Poly Adenosine Diphosphate (ADP) - Ribose Polymerase (PARP)</keyword>
  <keyword>Ovarian</keyword>
  <keyword>BRCA</keyword>
  <keyword>VELIA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Veliparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT02470585/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT02470585/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This trial was conducted at 188 sites in 10 countries (Australia, Brazil, Denmark, Israel, Japan, Poland, Republic of Korea, Spain, United Kingdom, and United States). The study is currently ongoing; the data-cutoff date for the primary analysis results reported below was May 3, 2019.</recruitment_details>
      <pre_assignment_details>Participants were randomized in a 1:1:1 ratio to one of three treatment groups. Randomization was stratified according to the timing of surgery and residual disease after primary surgery, the paclitaxel schedule, stage of disease, geographic region, and germline breast cancer susceptibility gene (BRCA) status.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo + Carboplatin + Paclitaxel -&gt; Placebo</title>
          <description>Participants received placebo to veliparib orally twice a day in combination with carboplatin given at an area under the curve (AUC) of 6 milligrams per milliliter per minute (mg/mL/min) every 3 weeks, and paclitaxel 175 mg per square meter (mg/m²) of body-surface area (BSA), administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.</description>
        </group>
        <group group_id="P2">
          <title>Veliparib + Carboplatin + Paclitaxel -&gt; Placebo</title>
          <description>Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.</description>
        </group>
        <group group_id="P3">
          <title>Veliparib + Carboplatin + Paclitaxel -&gt; Veliparib</title>
          <description>Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received single-agent veliparib at a dose of 300 mg twice daily for 2 weeks (transition period) and then 400 mg veliparib twice daily if the dose in the transition period was not associated with limiting side effects for an additional thirty 21-day cycles of maintenance therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="375"/>
                <participants group_id="P2" count="383"/>
                <participants group_id="P3" count="382"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="371"/>
                <participants group_id="P2" count="376"/>
                <participants group_id="P3" count="377"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="268"/>
                <participants group_id="P2" count="266"/>
                <participants group_id="P3" count="257"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="117"/>
                <participants group_id="P3" count="125"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="86"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The intention-to-treat (ITT) population consisted of all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo + Carboplatin + Paclitaxel -&gt; Placebo</title>
          <description>Participants received placebo to veliparib orally twice a day in combination with carboplatin given at an area under the curve [AUC] of 6 mg per milliliter per minute (mg/mL/min), every 3 weeks, and paclitaxel 175 mg per square meter (mg/m²) of body-surface area (BSA), administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.</description>
        </group>
        <group group_id="B2">
          <title>Veliparib + Carboplatin + Paclitaxel -&gt; Placebo</title>
          <description>Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.</description>
        </group>
        <group group_id="B3">
          <title>Veliparib + Carboplatin + Paclitaxel -&gt; Veliparib</title>
          <description>Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received single-agent veliparib at a dose of 300 mg twice daily for 2 weeks (transition period) and then 400 mg veliparib twice daily if the dose in the transition period was not associated with limiting side effects for an additional thirty 21-day cycles of maintenance therapy.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="375"/>
            <count group_id="B2" value="383"/>
            <count group_id="B3" value="382"/>
            <count group_id="B4" value="1140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="375"/>
                    <count group_id="B2" value="383"/>
                    <count group_id="B3" value="382"/>
                    <count group_id="B4" value="1140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.0" lower_limit="33.0" upper_limit="86.0"/>
                    <measurement group_id="B2" value="62.0" lower_limit="22.0" upper_limit="88.0"/>
                    <measurement group_id="B3" value="62.0" lower_limit="30.0" upper_limit="85.0"/>
                    <measurement group_id="B4" value="62.0" lower_limit="22.0" upper_limit="88.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="375"/>
                    <count group_id="B2" value="383"/>
                    <count group_id="B3" value="382"/>
                    <count group_id="B4" value="1140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt; 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="233"/>
                    <measurement group_id="B2" value="226"/>
                    <measurement group_id="B3" value="228"/>
                    <measurement group_id="B4" value="687"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="154"/>
                    <measurement group_id="B4" value="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="375"/>
                    <count group_id="B2" value="383"/>
                    <count group_id="B3" value="382"/>
                    <count group_id="B4" value="1140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="375"/>
                    <measurement group_id="B2" value="383"/>
                    <measurement group_id="B3" value="382"/>
                    <measurement group_id="B4" value="1140"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="375"/>
                    <count group_id="B2" value="383"/>
                    <count group_id="B3" value="382"/>
                    <count group_id="B4" value="1140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="347"/>
                    <measurement group_id="B2" value="356"/>
                    <measurement group_id="B3" value="356"/>
                    <measurement group_id="B4" value="1059"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="375"/>
                    <count group_id="B2" value="383"/>
                    <count group_id="B3" value="382"/>
                    <count group_id="B4" value="1140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="299"/>
                    <measurement group_id="B2" value="297"/>
                    <measurement group_id="B3" value="300"/>
                    <measurement group_id="B4" value="896"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="184"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multi-race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Geographic Region</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="375"/>
                    <count group_id="B2" value="383"/>
                    <count group_id="B3" value="382"/>
                    <count group_id="B4" value="1140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>North America</title>
                  <measurement_list>
                    <measurement group_id="B1" value="266"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="267"/>
                    <measurement group_id="B4" value="794"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Japan</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rest of World</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BRCA-Deficient Status</title>
          <description>The BRCA-mutation cohort was defined as participants who had deleterious or suspected deleterious germline (gBRCA) or tissue-based (tBRCA) mutations as determined by the Myriad BRACAnalysis® companion diagnostic (CDx) or myChoice® HRD CDx assay, respectively, in BRCA1 or BRCA2.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="375"/>
                    <count group_id="B2" value="383"/>
                    <count group_id="B3" value="382"/>
                    <count group_id="B4" value="1140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Germline or tissue BRCA1/2 mutation</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="298"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Germline or tissue BRCA1/2 wildtype</title>
                  <measurement_list>
                    <measurement group_id="B1" value="254"/>
                    <measurement group_id="B2" value="243"/>
                    <measurement group_id="B3" value="245"/>
                    <measurement group_id="B4" value="742"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Homologous Recombination Deficiency (HRD) Status</title>
          <description>The HRD cohort consisted of participants who had tumors that were BRCA-mutated or had HRD according to the Myriad myChoice® assay, on which a score of ≥ 33 was considered to indicate HRD status, and a score of &lt; 33 was considered to indicate non-HRD status.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="375"/>
                    <count group_id="B2" value="383"/>
                    <count group_id="B3" value="382"/>
                    <count group_id="B4" value="1140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>HRD</title>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="206"/>
                    <measurement group_id="B3" value="214"/>
                    <measurement group_id="B4" value="627"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-HRD</title>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="125"/>
                    <measurement group_id="B4" value="372"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage of Disease</title>
          <description>Staging of primary ovarian carcinomas according to the International Federation of Gynecology and Obstetrics (FIGO) criteria, based on clinical examination, surgical exploration, histologic characteristics and cytologic testing.&#xD;
STAGE III: Tumor involves 1 or both ovaries with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastases to the retroperitoneal lymph nodes.&#xD;
STAGE IV: Distant metastases excluding peritoneal metastases</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="375"/>
                    <count group_id="B2" value="383"/>
                    <count group_id="B3" value="382"/>
                    <count group_id="B4" value="1140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Stage III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="292"/>
                    <measurement group_id="B2" value="288"/>
                    <measurement group_id="B3" value="295"/>
                    <measurement group_id="B4" value="875"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stage IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="263"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of Surgery Received</title>
          <description>Cytoreductive surgery could be performed before randomization and the initiation of study treatment (primary) or after 3 cycles of study treatment (interval), determined at the discretion of the investigator.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="375"/>
                    <count group_id="B2" value="383"/>
                    <count group_id="B3" value="382"/>
                    <count group_id="B4" value="1140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Primary</title>
                  <measurement_list>
                    <measurement group_id="B1" value="250"/>
                    <measurement group_id="B2" value="253"/>
                    <measurement group_id="B3" value="261"/>
                    <measurement group_id="B4" value="764"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Interval</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="320"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No surgery received</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Residual Disease After Primary Surgery</title>
          <description>Data were collected after interval surgery after cycle 3.</description>
          <population>Participants who underwent primary surgery</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="250"/>
                    <count group_id="B2" value="253"/>
                    <count group_id="B3" value="261"/>
                    <count group_id="B4" value="764"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No residual disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="358"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Microscopic residual disease only</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="158"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Any macroscopic residual disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Residual Disease After Interval Surgery</title>
          <population>Participants who underwent interval surgery</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="107"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="99"/>
                    <count group_id="B4" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No residual disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Microscopic residual disease only</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Any macroscopic residual disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Paclitaxel Dosing Regimen</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="375"/>
                    <count group_id="B2" value="383"/>
                    <count group_id="B3" value="382"/>
                    <count group_id="B4" value="1140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Weekly</title>
                  <measurement_list>
                    <measurement group_id="B1" value="193"/>
                    <measurement group_id="B2" value="203"/>
                    <measurement group_id="B3" value="190"/>
                    <measurement group_id="B4" value="586"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Every 3 weeks</title>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="189"/>
                    <measurement group_id="B4" value="546"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Germline BRCA Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="375"/>
                    <count group_id="B2" value="383"/>
                    <count group_id="B3" value="382"/>
                    <count group_id="B4" value="1140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Germline BRCA1/2 mutation</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="214"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Germline BRCA1/2 wildtype</title>
                  <measurement_list>
                    <measurement group_id="B1" value="305"/>
                    <measurement group_id="B2" value="305"/>
                    <measurement group_id="B3" value="298"/>
                    <measurement group_id="B4" value="908"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS) in the BRCA-deficient Population</title>
        <description>PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death if disease progression was not reached. If the participant did not have an event of disease progression or death prior to the analysis cut-off date, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method. The analysis of PFS occurred when the protocol-specified number of PFS events was reached.&#xD;
Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.</description>
        <time_frame>From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.</time_frame>
        <population>Analyses were performed in 3 sequentially inclusive populations. The first analysis was conducted using the BRCA-mutation cohort which included participants with either a gBRCA and/or tBRCA deleterious or suspected deleterious mutation in BRCA1 or BRCA2.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Carboplatin + Paclitaxel -&gt; Placebo</title>
            <description>Participants received placebo to veliparib orally twice a day in combination with carboplatin given at an area under the curve [AUC] of 6 mg per milliliter per minute (mg/mL/min), every 3 weeks, and paclitaxel 175 mg per square meter (mg/m²) of body-surface area (BSA), administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>Veliparib + Carboplatin + Paclitaxel -&gt; Placebo</title>
            <description>Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.</description>
          </group>
          <group group_id="O3">
            <title>Veliparib + Carboplatin + Paclitaxel -&gt; Veliparib</title>
            <description>Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received single-agent veliparib at a dose of 300 mg twice daily for 2 weeks (transition period) and then 400 mg veliparib twice daily if the dose in the transition period was not associated with limiting side effects for an additional thirty 21-day cycles of maintenance therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS) in the BRCA-deficient Population</title>
          <description>PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death if disease progression was not reached. If the participant did not have an event of disease progression or death prior to the analysis cut-off date, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method. The analysis of PFS occurred when the protocol-specified number of PFS events was reached.&#xD;
Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.</description>
          <population>Analyses were performed in 3 sequentially inclusive populations. The first analysis was conducted using the BRCA-mutation cohort which included participants with either a gBRCA and/or tBRCA deleterious or suspected deleterious mutation in BRCA1 or BRCA2.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" lower_limit="17.8" upper_limit="29.1"/>
                    <measurement group_id="O2" value="21.1" lower_limit="17.0" upper_limit="25.5"/>
                    <measurement group_id="O3" value="34.7" lower_limit="31.8" upper_limit="NA">Could not be estimated due to the low number of events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The primary efficacy analyses compared investigator-assessed PFS in the Veliparib + Carboplatin + Paclitaxel -&gt; Veliparib group vs. the Placebo + Carboplatin + Paclitaxel -&gt; Placebo group.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Multiplicity considerations included 3 treatment arms, (2 pairwise comparisons), 3 sequentially inclusive populations (BRCA-mutation population, HRD population, and ITT population), and multiple endpoints. A fixed-sequence testing procedure was used to control the Type I error rate at 0.05 from the primary efficacy endpoints sequentially through the secondary efficacy endpoints.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>A 2-sided p-value of ≤ 0.05 was considered statistically significant in the following hierarchical testing sequence: PFS was to be compared first in the BRCA-mutation cohort, then in the HRD cohort, and then in the ITT population.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Stratified according to residual disease status and disease stage.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.435</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.277</ci_lower_limit>
            <ci_upper_limit>0.683</ci_upper_limit>
            <estimate_desc>Cox proportional hazards model stratified according to the same factors as those used in the log-rank test above.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS) in the Homologous Recombination Deficiency Cohort</title>
        <description>PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death if disease progression was not reached. If the participant did not have an event of disease progression or death, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method. The primary analysis of PFS occurred when the protocol-specified number of PFS events was reached and was performed in 3 sequentially inclusive populations.&#xD;
Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.&#xD;
.</description>
        <time_frame>From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.</time_frame>
        <population>Analyses were performed in 3 sequentially inclusive populations. The second analysis was conducted using the HRD cohort which included participants in the BRCA-mutation cohort and those determined to have HRD tumors.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Carboplatin + Paclitaxel -&gt; Placebo</title>
            <description>Participants received placebo to veliparib orally twice a day in combination with carboplatin given at an area under the curve [AUC] of 6 mg per milliliter per minute (mg/mL/min), every 3 weeks, and paclitaxel 175 mg per square meter (mg/m²) of body-surface area (BSA), administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>Veliparib + Carboplatin + Paclitaxel -&gt; Placebo</title>
            <description>Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.</description>
          </group>
          <group group_id="O3">
            <title>Veliparib + Carboplatin + Paclitaxel -&gt; Veliparib</title>
            <description>Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received single-agent veliparib at a dose of 300 mg twice daily for 2 weeks (transition period) and then 400 mg veliparib twice daily if the dose in the transition period was not associated with limiting side effects for an additional thirty 21-day cycles of maintenance therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS) in the Homologous Recombination Deficiency Cohort</title>
          <description>PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death if disease progression was not reached. If the participant did not have an event of disease progression or death, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method. The primary analysis of PFS occurred when the protocol-specified number of PFS events was reached and was performed in 3 sequentially inclusive populations.&#xD;
Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.&#xD;
.</description>
          <population>Analyses were performed in 3 sequentially inclusive populations. The second analysis was conducted using the HRD cohort which included participants in the BRCA-mutation cohort and those determined to have HRD tumors.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" lower_limit="17.8" upper_limit="22.8"/>
                    <measurement group_id="O2" value="18.1" lower_limit="16.4" upper_limit="22.7"/>
                    <measurement group_id="O3" value="31.9" lower_limit="25.8" upper_limit="38.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Multiplicity considerations included 3 treatment arms, (2 pairwise comparisons), 3 sequentially inclusive populations (BRCA-mutation population, HRD population, and ITT population), and multiple endpoints. A fixed-sequence testing procedure was used to control the Type I error rate at 0.05 from the primary efficacy endpoints sequentially through the secondary efficacy endpoints.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>A 2-sided p-value of ≤ 0.05 was considered statistically significant in the following hierarchical testing sequence: PFS was to be compared first in the BRCA-mutation cohort, then in the HRD cohort, and then in the ITT population.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Stratified according to residual disease status and disease stage.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.572</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.433</ci_lower_limit>
            <ci_upper_limit>0.756</ci_upper_limit>
            <estimate_desc>Cox proportional hazards model stratified according to the same factors as those used in the log-rank test above.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS) in the Intention-to-treat Population</title>
        <description>PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death (all causes of mortality) if disease progression was not reached. If the participant did not have an event of disease progression according to RECIST criteria (as or death, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method.&#xD;
Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.&#xD;
The primary analysis of PFS occurred when the protocol-specified number of PFS events was reached.</description>
        <time_frame>From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.</time_frame>
        <population>Analyses were performed in 3 sequentially inclusive populations. The third analysis was conducted using the intention-to-treat (ITT) population (all randomized participants).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Carboplatin + Paclitaxel -&gt; Placebo</title>
            <description>Participants received placebo to veliparib orally twice a day in combination with carboplatin given at an area under the curve [AUC] of 6 mg per milliliter per minute (mg/mL/min), every 3 weeks, and paclitaxel 175 mg per square meter (mg/m²) of body-surface area (BSA), administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>Veliparib + Carboplatin + Paclitaxel -&gt; Placebo</title>
            <description>Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.</description>
          </group>
          <group group_id="O3">
            <title>Veliparib + Carboplatin + Paclitaxel -&gt; Veliparib</title>
            <description>Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received single-agent veliparib at a dose of 300 mg twice daily for 2 weeks (transition period) and then 400 mg veliparib twice daily if the dose in the transition period was not associated with limiting side effects for an additional thirty 21-day cycles of maintenance therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS) in the Intention-to-treat Population</title>
          <description>PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death (all causes of mortality) if disease progression was not reached. If the participant did not have an event of disease progression according to RECIST criteria (as or death, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method.&#xD;
Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.&#xD;
The primary analysis of PFS occurred when the protocol-specified number of PFS events was reached.</description>
          <population>Analyses were performed in 3 sequentially inclusive populations. The third analysis was conducted using the intention-to-treat (ITT) population (all randomized participants).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="383"/>
                <count group_id="O3" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="15.1" upper_limit="19.1"/>
                    <measurement group_id="O2" value="15.2" lower_limit="14.1" upper_limit="17.3"/>
                    <measurement group_id="O3" value="23.5" lower_limit="19.3" upper_limit="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Multiplicity considerations included 3 treatment arms, (2 pairwise comparisons), 3 sequentially inclusive populations (BRCA-mutation population, HRD population, and ITT population), and multiple endpoints. A fixed-sequence testing procedure was used to control the Type I error rate at 0.05 from the primary efficacy endpoints sequentially through the secondary efficacy endpoints.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>A 2-sided p-value of ≤ 0.05 was considered statistically significant in the following hierarchical testing sequence: PFS was to be compared first in the BRCA-mutation cohort, then in the HRD cohort, and then in the ITT population.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Stratified according to residual disease status and disease stage, choice of the paclitaxel regimen, and BRCA-mutation status</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.683</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.562</ci_lower_limit>
            <ci_upper_limit>0.831</ci_upper_limit>
            <estimate_desc>Cox proportional hazards model stratified according to the same factors as those used in the log-rank test above.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS is defined as the time from the day the participant was randomized to the date of death. All events of death will be included, regardless of whether the event occurs while the participant is still taking study drug, or after discontinuation of study drug. If a participant has not died, then the data will be censored at the date the participant is last known to be alive.&#xD;
The final analysis of OS will occur when the pre-specified number of events has occurred in the ITT and HRD populations.</description>
        <time_frame>Approximately 8 years from randomization.</time_frame>
        <posting_date>03/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Related Symptom (DRS) Score in the BRCA-mutation Population</title>
        <description>The Disease Related Symptom score is a subset of the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18), which evaluates nine symptoms related to ovarian cancer. The NFOSI-18 DRS score ranges from 0 to 36, with higher scores indicating a lower burden of symptoms and a score of 0 being severely symptomatic. A 3-point difference was defined as clinically meaningful. A positive change from Baseline indicates improvement.&#xD;
Change from Baseline was calculated using a used a mixed-model for repeated measures (MMRM) with treatment, stratification factors of residual disease and stage of disease, time point and treatment-by-time point interaction as fixed effect factors, and Baseline DRS score as a covariate.&#xD;
DRS was not included in the fixed-sequence testing procedure.</description>
        <time_frame>Baseline and Day 1 of Cycles 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35</time_frame>
        <population>BRCA-mutation population, participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Carboplatin + Paclitaxel -&gt; Placebo</title>
            <description>Participants received placebo to veliparib orally twice a day in combination with carboplatin given at an area under the curve [AUC] of 6 mg per milliliter per minute (mg/mL/min), every 3 weeks, and paclitaxel 175 mg per square meter (mg/m²) of body-surface area (BSA), administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>Veliparib + Carboplatin + Paclitaxel -&gt; Placebo</title>
            <description>Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.</description>
          </group>
          <group group_id="O3">
            <title>Veliparib + Carboplatin + Paclitaxel -&gt; Veliparib</title>
            <description>Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received single-agent veliparib at a dose of 300 mg twice daily for 2 weeks (transition period) and then 400 mg veliparib twice daily if the dose in the transition period was not associated with limiting side effects for an additional thirty 21-day cycles of maintenance therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Related Symptom (DRS) Score in the BRCA-mutation Population</title>
          <description>The Disease Related Symptom score is a subset of the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18), which evaluates nine symptoms related to ovarian cancer. The NFOSI-18 DRS score ranges from 0 to 36, with higher scores indicating a lower burden of symptoms and a score of 0 being severely symptomatic. A 3-point difference was defined as clinically meaningful. A positive change from Baseline indicates improvement.&#xD;
Change from Baseline was calculated using a used a mixed-model for repeated measures (MMRM) with treatment, stratification factors of residual disease and stage of disease, time point and treatment-by-time point interaction as fixed effect factors, and Baseline DRS score as a covariate.&#xD;
DRS was not included in the fixed-sequence testing procedure.</description>
          <population>BRCA-mutation population, participants with available data at each time point.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.52"/>
                    <measurement group_id="O2" value="0.5" spread="0.53"/>
                    <measurement group_id="O3" value="0.9" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.57"/>
                    <measurement group_id="O2" value="0.7" spread="0.58"/>
                    <measurement group_id="O3" value="0.4" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.54"/>
                    <measurement group_id="O2" value="1.8" spread="0.54"/>
                    <measurement group_id="O3" value="1.8" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.60"/>
                    <measurement group_id="O2" value="3.3" spread="0.60"/>
                    <measurement group_id="O3" value="2.4" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.56"/>
                    <measurement group_id="O2" value="3.6" spread="0.55"/>
                    <measurement group_id="O3" value="2.9" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="0.57"/>
                    <measurement group_id="O2" value="3.8" spread="0.57"/>
                    <measurement group_id="O3" value="3.0" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="0.53"/>
                    <measurement group_id="O2" value="4.0" spread="0.54"/>
                    <measurement group_id="O3" value="3.4" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="0.56"/>
                    <measurement group_id="O2" value="4.0" spread="0.57"/>
                    <measurement group_id="O3" value="3.2" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="0.62"/>
                    <measurement group_id="O2" value="4.0" spread="0.63"/>
                    <measurement group_id="O3" value="2.7" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="0.59"/>
                    <measurement group_id="O2" value="3.9" spread="0.59"/>
                    <measurement group_id="O3" value="3.2" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="0.55"/>
                    <measurement group_id="O2" value="4.0" spread="0.55"/>
                    <measurement group_id="O3" value="2.8" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="0.58"/>
                    <measurement group_id="O2" value="5.0" spread="0.59"/>
                    <measurement group_id="O3" value="3.5" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="0.55"/>
                    <measurement group_id="O2" value="4.8" spread="0.56"/>
                    <measurement group_id="O3" value="3.0" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="0.66"/>
                    <measurement group_id="O2" value="5.3" spread="0.66"/>
                    <measurement group_id="O3" value="2.8" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0.56"/>
                    <measurement group_id="O2" value="4.8" spread="0.57"/>
                    <measurement group_id="O3" value="2.9" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="0.67"/>
                    <measurement group_id="O2" value="5.0" spread="0.66"/>
                    <measurement group_id="O3" value="3.9" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="0.64"/>
                    <measurement group_id="O2" value="4.6" spread="0.63"/>
                    <measurement group_id="O3" value="3.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Related Symptom (DRS) Score in the HRD Population</title>
        <description>The Disease Related Symptom score is a subset of the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18), which evaluates nine symptoms related to ovarian cancer. The NFOSI-18 DRS score ranges from 0 to 36, with higher scores indicating a lower burden of symptoms and a score of 0 being severely symptomatic. A 3-point difference was defined as clinically meaningful. A positive change from Baseline indicates improvement.&#xD;
Change from Baseline was calculated using a used a mixed-model for repeated measures (MMRM) with treatment, stratification factors of residual disease and stage of disease, time point and treatment-by-time point interaction as fixed effect factors, and Baseline DRS score as a covariate.&#xD;
DRS was not included in the fixed-sequence testing procedure.</description>
        <time_frame>Baseline and Day 1 of Cycles 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35</time_frame>
        <population>HRD population, participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Carboplatin + Paclitaxel -&gt; Placebo</title>
            <description>Participants received placebo to veliparib orally twice a day in combination with carboplatin given at an area under the curve [AUC] of 6 mg per milliliter per minute (mg/mL/min), every 3 weeks, and paclitaxel 175 mg per square meter (mg/m²) of body-surface area (BSA), administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>Veliparib + Carboplatin + Paclitaxel -&gt; Placebo</title>
            <description>Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.</description>
          </group>
          <group group_id="O3">
            <title>Veliparib + Carboplatin + Paclitaxel -&gt; Veliparib</title>
            <description>Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received single-agent veliparib at a dose of 300 mg twice daily for 2 weeks (transition period) and then 400 mg veliparib twice daily if the dose in the transition period was not associated with limiting side effects for an additional thirty 21-day cycles of maintenance therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Related Symptom (DRS) Score in the HRD Population</title>
          <description>The Disease Related Symptom score is a subset of the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18), which evaluates nine symptoms related to ovarian cancer. The NFOSI-18 DRS score ranges from 0 to 36, with higher scores indicating a lower burden of symptoms and a score of 0 being severely symptomatic. A 3-point difference was defined as clinically meaningful. A positive change from Baseline indicates improvement.&#xD;
Change from Baseline was calculated using a used a mixed-model for repeated measures (MMRM) with treatment, stratification factors of residual disease and stage of disease, time point and treatment-by-time point interaction as fixed effect factors, and Baseline DRS score as a covariate.&#xD;
DRS was not included in the fixed-sequence testing procedure.</description>
          <population>HRD population, participants with available data at each time point.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="186"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.35"/>
                    <measurement group_id="O2" value="0.5" spread="0.36"/>
                    <measurement group_id="O3" value="0.9" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="178"/>
                    <count group_id="O2" value="169"/>
                    <count group_id="O3" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.37"/>
                    <measurement group_id="O2" value="1.1" spread="0.37"/>
                    <measurement group_id="O3" value="0.8" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="168"/>
                    <count group_id="O3" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.35"/>
                    <measurement group_id="O2" value="1.8" spread="0.36"/>
                    <measurement group_id="O3" value="2.2" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="173"/>
                    <count group_id="O2" value="165"/>
                    <count group_id="O3" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.37"/>
                    <measurement group_id="O2" value="3.6" spread="0.38"/>
                    <measurement group_id="O3" value="2.3" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="161"/>
                    <count group_id="O3" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="0.36"/>
                    <measurement group_id="O2" value="3.5" spread="0.36"/>
                    <measurement group_id="O3" value="2.7" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="160"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="0.37"/>
                    <measurement group_id="O2" value="3.8" spread="0.38"/>
                    <measurement group_id="O3" value="2.7" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="130"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="0.35"/>
                    <measurement group_id="O2" value="3.9" spread="0.36"/>
                    <measurement group_id="O3" value="3.3" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="0.39"/>
                    <measurement group_id="O2" value="3.4" spread="0.41"/>
                    <measurement group_id="O3" value="3.0" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="0.40"/>
                    <measurement group_id="O2" value="3.7" spread="0.42"/>
                    <measurement group_id="O3" value="2.7" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="115"/>
                    <count group_id="O2" value="110"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="0.40"/>
                    <measurement group_id="O2" value="3.6" spread="0.41"/>
                    <measurement group_id="O3" value="3.0" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="0.38"/>
                    <measurement group_id="O2" value="3.6" spread="0.39"/>
                    <measurement group_id="O3" value="3.2" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="0.40"/>
                    <measurement group_id="O2" value="4.4" spread="0.41"/>
                    <measurement group_id="O3" value="3.5" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="0.39"/>
                    <measurement group_id="O2" value="4.4" spread="0.40"/>
                    <measurement group_id="O3" value="3.0" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="0.43"/>
                    <measurement group_id="O2" value="4.7" spread="0.44"/>
                    <measurement group_id="O3" value="3.2" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="0.41"/>
                    <measurement group_id="O2" value="4.3" spread="0.42"/>
                    <measurement group_id="O3" value="3.3" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="0.45"/>
                    <measurement group_id="O2" value="4.7" spread="0.45"/>
                    <measurement group_id="O3" value="3.9" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="0.46"/>
                    <measurement group_id="O2" value="4.6" spread="0.47"/>
                    <measurement group_id="O3" value="3.3" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Related Symptom (DRS) Score in the ITT Population</title>
        <description>The Disease Related Symptom score is a subset of the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18), which evaluates nine symptoms related to ovarian cancer. The NFOSI-18 DRS score ranges from 0 to 36, with higher scores indicating a lower burden of symptoms and a score of 0 being severely symptomatic. A 3-point difference was defined as clinically meaningful. A positive change from Baseline indicates improvement.&#xD;
Change from Baseline was calculated using a used a mixed-model for repeated measures (MMRM) with treatment, stratification factors of residual disease, stage of disease, choice of paclitaxel dosing regimen and BRCA-deficient status, time point and treatment-by-time point interaction as fixed effect factors, and Baseline DRS score as a covariate.&#xD;
DRS was not included in the fixed-sequence testing procedure.</description>
        <time_frame>Baseline and Day 1 of Cycles 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35</time_frame>
        <population>ITT population, participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Carboplatin + Paclitaxel -&gt; Placebo</title>
            <description>Participants received placebo to veliparib orally twice a day in combination with carboplatin given at an area under the curve [AUC] of 6 mg per milliliter per minute (mg/mL/min), every 3 weeks, and paclitaxel 175 mg per square meter (mg/m²) of body-surface area (BSA), administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>Veliparib + Carboplatin + Paclitaxel -&gt; Placebo</title>
            <description>Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.</description>
          </group>
          <group group_id="O3">
            <title>Veliparib + Carboplatin + Paclitaxel -&gt; Veliparib</title>
            <description>Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received single-agent veliparib at a dose of 300 mg twice daily for 2 weeks (transition period) and then 400 mg veliparib twice daily if the dose in the transition period was not associated with limiting side effects for an additional thirty 21-day cycles of maintenance therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Related Symptom (DRS) Score in the ITT Population</title>
          <description>The Disease Related Symptom score is a subset of the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18), which evaluates nine symptoms related to ovarian cancer. The NFOSI-18 DRS score ranges from 0 to 36, with higher scores indicating a lower burden of symptoms and a score of 0 being severely symptomatic. A 3-point difference was defined as clinically meaningful. A positive change from Baseline indicates improvement.&#xD;
Change from Baseline was calculated using a used a mixed-model for repeated measures (MMRM) with treatment, stratification factors of residual disease, stage of disease, choice of paclitaxel dosing regimen and BRCA-deficient status, time point and treatment-by-time point interaction as fixed effect factors, and Baseline DRS score as a covariate.&#xD;
DRS was not included in the fixed-sequence testing procedure.</description>
          <population>ITT population, participants with available data at each time point.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="383"/>
                <count group_id="O3" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="333"/>
                    <count group_id="O2" value="332"/>
                    <count group_id="O3" value="319"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.28"/>
                    <measurement group_id="O2" value="0.4" spread="0.28"/>
                    <measurement group_id="O3" value="1.0" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="310"/>
                    <count group_id="O2" value="311"/>
                    <count group_id="O3" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.29"/>
                    <measurement group_id="O2" value="0.9" spread="0.29"/>
                    <measurement group_id="O3" value="0.8" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="301"/>
                    <count group_id="O2" value="300"/>
                    <count group_id="O3" value="287"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.29"/>
                    <measurement group_id="O2" value="1.8" spread="0.29"/>
                    <measurement group_id="O3" value="2.1" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="291"/>
                    <count group_id="O2" value="290"/>
                    <count group_id="O3" value="277"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.29"/>
                    <measurement group_id="O2" value="3.8" spread="0.29"/>
                    <measurement group_id="O3" value="2.4" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="269"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="0.29"/>
                    <measurement group_id="O2" value="4.0" spread="0.28"/>
                    <measurement group_id="O3" value="3.0" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="254"/>
                    <count group_id="O3" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="0.30"/>
                    <measurement group_id="O2" value="4.0" spread="0.30"/>
                    <measurement group_id="O3" value="3.2" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="224"/>
                    <count group_id="O2" value="225"/>
                    <count group_id="O3" value="207"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="0.30"/>
                    <measurement group_id="O2" value="3.8" spread="0.30"/>
                    <measurement group_id="O3" value="3.3" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="202"/>
                    <count group_id="O3" value="202"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="0.32"/>
                    <measurement group_id="O2" value="3.7" spread="0.32"/>
                    <measurement group_id="O3" value="3.4" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="0.32"/>
                    <measurement group_id="O2" value="4.0" spread="0.32"/>
                    <measurement group_id="O3" value="3.1" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="174"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="0.34"/>
                    <measurement group_id="O2" value="3.6" spread="0.34"/>
                    <measurement group_id="O3" value="3.3" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="150"/>
                    <count group_id="O2" value="139"/>
                    <count group_id="O3" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="0.33"/>
                    <measurement group_id="O2" value="3.9" spread="0.33"/>
                    <measurement group_id="O3" value="3.4" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="127"/>
                    <count group_id="O3" value="145"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="0.34"/>
                    <measurement group_id="O2" value="4.1" spread="0.35"/>
                    <measurement group_id="O3" value="3.5" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="130"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="0.33"/>
                    <measurement group_id="O2" value="4.2" spread="0.33"/>
                    <measurement group_id="O3" value="3.5" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="0.35"/>
                    <measurement group_id="O2" value="4.4" spread="0.35"/>
                    <measurement group_id="O3" value="3.4" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="0.36"/>
                    <measurement group_id="O2" value="4.1" spread="0.37"/>
                    <measurement group_id="O3" value="3.3" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="0.38"/>
                    <measurement group_id="O2" value="4.5" spread="0.38"/>
                    <measurement group_id="O3" value="3.8" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="0.38"/>
                    <measurement group_id="O2" value="4.2" spread="0.38"/>
                    <measurement group_id="O3" value="3.8" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of study drug and no more than 30 days after the last dose of any study treatment up to the data cut-off date of 03 May 2019; median duration of treatment with veliparib/placebo was 369 days (range: 1 to 840 days).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo + Carboplatin + Paclitaxel -&gt; Placebo</title>
          <description>Participants received placebo to veliparib orally twice a day in combination with carboplatin given at an area under the curve [AUC] of 6 mg per milliliter per minute (mg/mL/min), every 3 weeks, and paclitaxel 175 mg per square meter (mg/m²) of body-surface area (BSA), administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.</description>
        </group>
        <group group_id="E2">
          <title>Veliparib + Carboplatin + Paclitaxel -&gt; Placebo</title>
          <description>Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.</description>
        </group>
        <group group_id="E3">
          <title>Veliparib + Carboplatin + Paclitaxel -&gt; Veliparib</title>
          <description>Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.&#xD;
Participants who completed chemotherapy without disease progression received single-agent veliparib at a dose of 300 mg twice daily for 2 weeks (transition period) and then 400 mg veliparib twice daily if the dose in the transition period was not associated with limiting side effects for an additional thirty 21-day cycles of maintenance therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="371"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="88" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="371"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="141" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="376"/>
                <counts group_id="E3" events="18" subjects_affected="14" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="371"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="376"/>
                <counts group_id="E3" events="17" subjects_affected="15" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E2" events="22" subjects_affected="16" subjects_at_risk="376"/>
                <counts group_id="E3" events="16" subjects_affected="12" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="376"/>
                <counts group_id="E3" events="20" subjects_affected="10" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>STRESS CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>VENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>ADRENAL INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ADHESIONS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ABDOMINAL HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ABDOMINAL INCARCERATED HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="376"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>COLITIS ULCERATIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="376"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="376"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>DIVERTICULAR PERFORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>EPIPLOIC APPENDAGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>GASTRIC VOLVULUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HIATUS HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ILEAL PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="376"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>INTESTINAL PSEUDO-OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>INTRA-ABDOMINAL FLUID COLLECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE PERFORATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>MECHANICAL ILEUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="376"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS ULCERATIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PERITONEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PNEUMOPERITONEUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="371"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="376"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>SPIGELIAN HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="376"/>
                <counts group_id="E3" events="16" subjects_affected="12" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>DISEASE PROGRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>INCARCERATED HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PELVIC MASS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="376"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>BACTEROIDES BACTERAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>CATHETER SITE INFECTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE INFECTION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>COLONIC ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>EMPYEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ENTEROBACTER INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ENTEROCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS INFECTIOUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>GROIN ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>INFECTED LYMPHOCELE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>INFECTIOUS COLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="376"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISCITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>LYMPHANGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>MENINGITIS CRYPTOCOCCAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>MYCOBACTERIAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>NAIL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>OPHTHALMIC HERPES ZOSTER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PELVIC ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PELVIC INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PERIORBITAL CELLULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PERITONEAL ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PERITONITIS BACTERIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS STREPTOCOCCAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PHLEBITIS INFECTIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="376"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>SEPTIC EMBOLUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="376"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>SUBDIAPHRAGMATIC ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>SYSTEMIC CANDIDA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="376"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACETABULUM FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC LEAK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>FRACTURED SACRUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL STOMA COMPLICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HEAT ILLNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>INCISIONAL HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>INTESTINAL ANASTOMOSIS COMPLICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>MULTIPLE INJURIES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PELVIC FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>SKELETAL INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>SPINAL FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>THORACIC VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>VAGINAL CUFF DEHISCENCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>WOUND COMPLICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>WOUND DECOMPOSITION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>SOLUBLE FIBRIN MONOMER COMPLEX INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HYPOALBUMINAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>FLANK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYELOID LEUKAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>MALIGNANT NEOPLASM PROGRESSION</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="371"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="376"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>MALIGNANT PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>METASTASES TO CENTRAL NERVOUS SYSTEM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>OVARIAN CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL ARTERY EMBOLISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HYPERSOMNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL VENOUS SINUS THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>MIGRAINE WITH AURA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>NEURALGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>DEVICE BREAKAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>DEVICE DISLOCATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE KIDNEY INJURY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>RENAL VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>URETEROLITHIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>FEMALE GENITAL TRACT FISTULA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX SPONTANEOUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="371"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="376"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PULMONARY THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT CONGESTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>EMBOLISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>JUGULAR VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>LYMPHOCELE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PHLEBITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>SUBCLAVIAN VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="369" subjects_at_risk="371"/>
                <counts group_id="E2" subjects_affected="375" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="376" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="513" subjects_affected="191" subjects_at_risk="371"/>
                <counts group_id="E2" events="597" subjects_affected="232" subjects_at_risk="376"/>
                <counts group_id="E3" events="657" subjects_affected="226" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="223" subjects_affected="89" subjects_at_risk="371"/>
                <counts group_id="E2" events="260" subjects_affected="86" subjects_at_risk="376"/>
                <counts group_id="E3" events="325" subjects_affected="112" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <counts group_id="E1" events="28" subjects_affected="15" subjects_at_risk="371"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="376"/>
                <counts group_id="E3" events="57" subjects_affected="26" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="680" subjects_affected="245" subjects_at_risk="371"/>
                <counts group_id="E2" events="875" subjects_affected="265" subjects_at_risk="376"/>
                <counts group_id="E3" events="840" subjects_affected="272" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="266" subjects_affected="119" subjects_at_risk="371"/>
                <counts group_id="E2" events="626" subjects_affected="216" subjects_at_risk="376"/>
                <counts group_id="E3" events="721" subjects_affected="209" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" events="33" subjects_affected="31" subjects_at_risk="371"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="376"/>
                <counts group_id="E3" events="27" subjects_affected="27" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" events="55" subjects_affected="45" subjects_at_risk="371"/>
                <counts group_id="E2" events="54" subjects_affected="48" subjects_at_risk="376"/>
                <counts group_id="E3" events="39" subjects_affected="34" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="162" subjects_affected="113" subjects_at_risk="371"/>
                <counts group_id="E2" events="142" subjects_affected="104" subjects_at_risk="376"/>
                <counts group_id="E3" events="162" subjects_affected="118" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="38" subjects_affected="29" subjects_at_risk="371"/>
                <counts group_id="E2" events="24" subjects_affected="18" subjects_at_risk="376"/>
                <counts group_id="E3" events="36" subjects_affected="28" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="203" subjects_affected="157" subjects_at_risk="371"/>
                <counts group_id="E2" events="238" subjects_affected="176" subjects_at_risk="376"/>
                <counts group_id="E3" events="225" subjects_affected="163" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="246" subjects_affected="149" subjects_at_risk="371"/>
                <counts group_id="E2" events="225" subjects_affected="136" subjects_at_risk="376"/>
                <counts group_id="E3" events="254" subjects_affected="164" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="371"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="376"/>
                <counts group_id="E3" events="23" subjects_affected="22" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="54" subjects_affected="41" subjects_at_risk="371"/>
                <counts group_id="E2" events="55" subjects_affected="45" subjects_at_risk="376"/>
                <counts group_id="E3" events="41" subjects_affected="35" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="371"/>
                <counts group_id="E2" events="30" subjects_affected="28" subjects_at_risk="376"/>
                <counts group_id="E3" events="47" subjects_affected="35" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="425" subjects_affected="247" subjects_at_risk="371"/>
                <counts group_id="E2" events="432" subjects_affected="258" subjects_at_risk="376"/>
                <counts group_id="E3" events="575" subjects_affected="289" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" events="66" subjects_affected="51" subjects_at_risk="371"/>
                <counts group_id="E2" events="52" subjects_affected="47" subjects_at_risk="376"/>
                <counts group_id="E3" events="67" subjects_affected="59" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="210" subjects_affected="127" subjects_at_risk="371"/>
                <counts group_id="E2" events="169" subjects_affected="123" subjects_at_risk="376"/>
                <counts group_id="E3" events="308" subjects_affected="174" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="58" subjects_affected="28" subjects_at_risk="371"/>
                <counts group_id="E2" events="55" subjects_affected="36" subjects_at_risk="376"/>
                <counts group_id="E3" events="64" subjects_affected="41" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="355" subjects_affected="222" subjects_at_risk="371"/>
                <counts group_id="E2" events="407" subjects_affected="235" subjects_at_risk="376"/>
                <counts group_id="E3" events="450" subjects_affected="257" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="371"/>
                <counts group_id="E2" events="26" subjects_affected="19" subjects_at_risk="376"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="34" subjects_affected="21" subjects_at_risk="371"/>
                <counts group_id="E2" events="28" subjects_affected="20" subjects_at_risk="376"/>
                <counts group_id="E3" events="37" subjects_affected="31" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="371"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="376"/>
                <counts group_id="E3" events="21" subjects_affected="18" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="84" subjects_affected="73" subjects_at_risk="371"/>
                <counts group_id="E2" events="61" subjects_affected="57" subjects_at_risk="376"/>
                <counts group_id="E3" events="76" subjects_affected="56" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="26" subjects_affected="23" subjects_at_risk="371"/>
                <counts group_id="E2" events="31" subjects_affected="22" subjects_at_risk="376"/>
                <counts group_id="E3" events="23" subjects_affected="21" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="371"/>
                <counts group_id="E2" events="37" subjects_affected="33" subjects_at_risk="376"/>
                <counts group_id="E3" events="29" subjects_affected="22" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" events="84" subjects_affected="64" subjects_at_risk="371"/>
                <counts group_id="E2" events="64" subjects_affected="48" subjects_at_risk="376"/>
                <counts group_id="E3" events="58" subjects_affected="53" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="371"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="376"/>
                <counts group_id="E3" events="30" subjects_affected="25" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="26" subjects_affected="18" subjects_at_risk="371"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="376"/>
                <counts group_id="E3" events="22" subjects_affected="21" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="54" subjects_affected="44" subjects_at_risk="371"/>
                <counts group_id="E2" events="37" subjects_affected="29" subjects_at_risk="376"/>
                <counts group_id="E3" events="43" subjects_affected="34" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="104" subjects_affected="67" subjects_at_risk="371"/>
                <counts group_id="E2" events="90" subjects_affected="64" subjects_at_risk="376"/>
                <counts group_id="E3" events="90" subjects_affected="69" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="371"/>
                <counts group_id="E2" events="21" subjects_affected="17" subjects_at_risk="376"/>
                <counts group_id="E3" events="28" subjects_affected="20" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" events="47" subjects_affected="38" subjects_at_risk="371"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="376"/>
                <counts group_id="E3" events="25" subjects_affected="25" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="64" subjects_affected="41" subjects_at_risk="371"/>
                <counts group_id="E2" events="54" subjects_affected="30" subjects_at_risk="376"/>
                <counts group_id="E3" events="52" subjects_affected="40" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="46" subjects_affected="31" subjects_at_risk="371"/>
                <counts group_id="E2" events="39" subjects_affected="21" subjects_at_risk="376"/>
                <counts group_id="E3" events="35" subjects_affected="31" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>BLOOD ALKALINE PHOSPHATASE INCREASED</sub_title>
                <counts group_id="E1" events="26" subjects_affected="19" subjects_at_risk="371"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="376"/>
                <counts group_id="E3" events="21" subjects_affected="16" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="45" subjects_affected="32" subjects_at_risk="371"/>
                <counts group_id="E2" events="52" subjects_affected="41" subjects_at_risk="376"/>
                <counts group_id="E3" events="71" subjects_affected="54" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" events="48" subjects_affected="35" subjects_at_risk="371"/>
                <counts group_id="E2" events="34" subjects_affected="26" subjects_at_risk="376"/>
                <counts group_id="E3" events="51" subjects_affected="36" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="101" subjects_affected="85" subjects_at_risk="371"/>
                <counts group_id="E2" events="105" subjects_affected="81" subjects_at_risk="376"/>
                <counts group_id="E3" events="141" subjects_affected="110" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="371"/>
                <counts group_id="E2" events="48" subjects_affected="32" subjects_at_risk="376"/>
                <counts group_id="E3" events="36" subjects_affected="30" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="35" subjects_affected="18" subjects_at_risk="371"/>
                <counts group_id="E2" events="25" subjects_affected="17" subjects_at_risk="376"/>
                <counts group_id="E3" events="50" subjects_affected="27" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HYPOALBUMINAEMIA</sub_title>
                <counts group_id="E1" events="31" subjects_affected="19" subjects_at_risk="371"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="376"/>
                <counts group_id="E3" events="31" subjects_affected="16" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" events="26" subjects_affected="15" subjects_at_risk="371"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="376"/>
                <counts group_id="E3" events="40" subjects_affected="19" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="107" subjects_affected="69" subjects_at_risk="371"/>
                <counts group_id="E2" events="109" subjects_affected="66" subjects_at_risk="376"/>
                <counts group_id="E3" events="94" subjects_affected="59" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" events="198" subjects_affected="98" subjects_at_risk="371"/>
                <counts group_id="E2" events="140" subjects_affected="94" subjects_at_risk="376"/>
                <counts group_id="E3" events="141" subjects_affected="84" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" events="33" subjects_affected="25" subjects_at_risk="371"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="376"/>
                <counts group_id="E3" events="34" subjects_affected="25" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HYPOPHOSPHATAEMIA</sub_title>
                <counts group_id="E1" events="30" subjects_affected="21" subjects_at_risk="371"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="376"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="189" subjects_affected="123" subjects_at_risk="371"/>
                <counts group_id="E2" events="142" subjects_affected="106" subjects_at_risk="376"/>
                <counts group_id="E3" events="152" subjects_affected="106" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="88" subjects_affected="66" subjects_at_risk="371"/>
                <counts group_id="E2" events="75" subjects_affected="66" subjects_at_risk="376"/>
                <counts group_id="E3" events="86" subjects_affected="66" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" events="46" subjects_affected="27" subjects_at_risk="371"/>
                <counts group_id="E2" events="37" subjects_affected="26" subjects_at_risk="376"/>
                <counts group_id="E3" events="36" subjects_affected="33" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" events="28" subjects_affected="23" subjects_at_risk="371"/>
                <counts group_id="E2" events="34" subjects_affected="24" subjects_at_risk="376"/>
                <counts group_id="E3" events="33" subjects_affected="23" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" events="30" subjects_affected="24" subjects_at_risk="371"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="376"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="106" subjects_affected="75" subjects_at_risk="371"/>
                <counts group_id="E2" events="80" subjects_affected="59" subjects_at_risk="376"/>
                <counts group_id="E3" events="96" subjects_affected="69" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="68" subjects_affected="55" subjects_at_risk="371"/>
                <counts group_id="E2" events="56" subjects_affected="46" subjects_at_risk="376"/>
                <counts group_id="E3" events="63" subjects_affected="50" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="119" subjects_affected="89" subjects_at_risk="371"/>
                <counts group_id="E2" events="103" subjects_affected="81" subjects_at_risk="376"/>
                <counts group_id="E3" events="123" subjects_affected="98" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" events="89" subjects_affected="73" subjects_at_risk="371"/>
                <counts group_id="E2" events="73" subjects_affected="62" subjects_at_risk="376"/>
                <counts group_id="E3" events="99" subjects_affected="89" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="136" subjects_affected="97" subjects_at_risk="371"/>
                <counts group_id="E2" events="124" subjects_affected="90" subjects_at_risk="376"/>
                <counts group_id="E3" events="139" subjects_affected="97" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" events="413" subjects_affected="256" subjects_at_risk="371"/>
                <counts group_id="E2" events="347" subjects_affected="236" subjects_at_risk="376"/>
                <counts group_id="E3" events="371" subjects_affected="242" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="371"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="376"/>
                <counts group_id="E3" events="26" subjects_affected="23" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="71" subjects_affected="57" subjects_at_risk="371"/>
                <counts group_id="E2" events="75" subjects_affected="62" subjects_at_risk="376"/>
                <counts group_id="E3" events="69" subjects_affected="58" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="47" subjects_affected="40" subjects_at_risk="371"/>
                <counts group_id="E2" events="58" subjects_affected="46" subjects_at_risk="376"/>
                <counts group_id="E3" events="42" subjects_affected="34" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="103" subjects_affected="87" subjects_at_risk="371"/>
                <counts group_id="E2" events="142" subjects_affected="121" subjects_at_risk="376"/>
                <counts group_id="E3" events="135" subjects_affected="110" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="371"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="376"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="70" subjects_affected="58" subjects_at_risk="371"/>
                <counts group_id="E2" events="63" subjects_affected="57" subjects_at_risk="376"/>
                <counts group_id="E3" events="68" subjects_affected="58" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="106" subjects_affected="75" subjects_at_risk="371"/>
                <counts group_id="E2" events="110" subjects_affected="90" subjects_at_risk="376"/>
                <counts group_id="E3" events="109" subjects_affected="83" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="70" subjects_affected="59" subjects_at_risk="371"/>
                <counts group_id="E2" events="66" subjects_affected="61" subjects_at_risk="376"/>
                <counts group_id="E3" events="60" subjects_affected="55" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" events="30" subjects_affected="26" subjects_at_risk="371"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="376"/>
                <counts group_id="E3" events="22" subjects_affected="18" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="45" subjects_affected="38" subjects_at_risk="371"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="376"/>
                <counts group_id="E3" events="32" subjects_affected="27" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="272" subjects_affected="215" subjects_at_risk="371"/>
                <counts group_id="E2" events="271" subjects_affected="216" subjects_at_risk="376"/>
                <counts group_id="E3" events="255" subjects_affected="197" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>NAIL DISCOLOURATION</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="371"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="376"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="45" subjects_affected="38" subjects_at_risk="371"/>
                <counts group_id="E2" events="36" subjects_affected="32" subjects_at_risk="376"/>
                <counts group_id="E3" events="29" subjects_affected="25" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="67" subjects_affected="54" subjects_at_risk="371"/>
                <counts group_id="E2" events="62" subjects_affected="52" subjects_at_risk="376"/>
                <counts group_id="E3" events="52" subjects_affected="47" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>RASH MACULO-PAPULAR</sub_title>
                <counts group_id="E1" events="36" subjects_affected="31" subjects_at_risk="371"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="376"/>
                <counts group_id="E3" events="31" subjects_affected="22" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HOT FLUSH</sub_title>
                <counts group_id="E1" events="53" subjects_affected="49" subjects_at_risk="371"/>
                <counts group_id="E2" events="48" subjects_affected="44" subjects_at_risk="376"/>
                <counts group_id="E3" events="49" subjects_affected="42" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="65" subjects_affected="37" subjects_at_risk="371"/>
                <counts group_id="E2" events="61" subjects_affected="38" subjects_at_risk="376"/>
                <counts group_id="E3" events="55" subjects_affected="31" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie</organization>
      <phone>1-800-633-9110</phone>
      <email>abbvieclinicaltrials@abbvie.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

